Wednesday, July 2, 2025 7/2/2025

Mesenchymal Vascular Progenitor Depletion Promotes Lung Aging and Susceptibility to Emphysema

Award Number: R35HL161238
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2022
PERIOD OF PERFORMANCE END DATE: 12/31/2028

Group Awards By:

View Award Description

Mesenchymal Vascular Progenitor Depletion Promotes Lung Aging and Susceptibility to Emphysema - The overall mission of this research program is to define how pulmonary Mesenchymal Vascular Progenitor Depletion Promotes Lung Aging and Susceptibility to Emphysema. Loss of epithelial progenitor cell function is a unifying factor in accelerated lung aging, and the development of emphysema. However, equally as important but poorly understood, there is a gap in our understanding of mesenchymal vascular progenitors (MVPC) in these processes. This proposal is significant as it attempts to fill in a number of important gaps surrounding how dysfunction of the MVPC progenitor population, contributes to aging and increased susceptibility to emphysema via regulation of vascular remodeling and loss of angiostasis. Analysis of the MVPC - lung niche interactions provide a target rich environment to identify nuances in MVPC progenitor dependent pathways relevant to the pathobiology of Angiostasis, Aging and Emphysema, as well as the potential to identify therapeutics to restore tissue function. We propose three focus areas for our research based on complementary themes. Theme 1 Regulation of MVPC function in healthy and aged lung: we will use our unique in vivo and in vitro model systems to identify how MVPC function and adaptive angiogenesis is regulated during tissue homeostasis and aging. Theme 2 Consequence of MVPC Loss of Function in healthy, aged and cigarette smoke exposed lung: we will show that loss of MVPC function, by depletion or altered signaling, drives vasculopathy and subsequent lung aging and emphysema. Theme 3 Therapeutic Rescue of MVPC function in aged and cigarette smoke exposed lung: we will validate the use of MVPC and repurposing of FDA approved paquinimod to restore MVPC numbers and function, subsequent tissue function and establish time frames for intervention. Positive results from these studies are readily translatable. We will leverage our strong collaborations, at National Jewish, University of Colorado as well as internationally recognized collaborators provide a basic and translational understanding of the mechanisms regulating MVPC function and differentiation at the single cell level as well as how they regulate their niche and lung microenvironment. We will also define whether progenitor rescue with MVPC cell therapy or interventional treatment will restore lung structure and function.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $896,400 )
2025	2025	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	4	1/8/2025	NON-COMPETING CONTINUATION	$896,400
														Subtotal = $896,400

Issue Date FY: 2024 ( Subtotal = $976,079 )
2024	2024	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	002	3	6/20/2024	NON-COMPETING CONTINUATION	$79,680
2024	2024	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	001	3	1/29/2024	NON-COMPETING CONTINUATION	$896,399
2024	2023	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	2	10/30/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $976,079

Issue Date FY: 2023 ( Subtotal = $996,000 )
2023	2023	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	2	6/8/2023	NON-COMPETING CONTINUATION	$996,000
														Subtotal = $996,000

Issue Date FY: 2022 ( Subtotal = $996,000 )
2022	2022	NATIONAL JEWISH HEALTH	1400 JACKSON ST	DENVER	CO	80206	DENVER	USA	Lung Diseases Research	000	1	12/20/2021	NEW	$996,000
														Subtotal = $996,000

Grand Total All Awards = $3,864,479

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mesenchymal Vascular Progenitor Depletion Promotes Lung Aging and Susceptibility to Emphysema

Award Number: R35HL161238

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2022

PERIOD OF PERFORMANCE END DATE: 12/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer